A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV DNA vaccine; HIV vaccine; MVA HIV vaccine
- Indications HIV-1 infections
- Focus Adverse reactions
Most Recent Events
- 30 Apr 2014 Biomarkers information updated
- 03 Feb 2012 Actual initiation date (Oct 2010) added as reported by ClinicalTrials.gov.
- 03 Feb 2012 Planned End Date changed from 1 Feb 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.